Prescribing new drugs: a survey of hospital consultants in the West Midlands
Open Access
- 1 December 2000
- journal article
- Published by Oxford University Press (OUP) in International Journal of Pharmacy Practice
- Vol. 8 (4) , 285-290
- https://doi.org/10.1111/j.2042-7174.2000.tb01017.x
Abstract
Objective To investigate the factors that influence how consultants introduce new drugs into their clinical practice. Method A postal questionnaire survey of hospital consultants. Setting 169 consultants in medical specialties in six hospitals (general or teaching hospitals) in the West Midlands region, United Kingdom. Key findings Ninety-two completed questionnaires (54 per cent) were returned. Eighty consultants (87 per cent) reported using a new drug in the previous two years; 60 (65 per cent) had used either one or two new drugs and these were generally in their specialist field. There was no significant difference between hospitals in how easy it was to introduce a new drug. Sixty-one consultants (67 per cent) said that the procedure required an application to the hospital drug and therapeutics committee. Consultants frequently asked patients' general practitioners to prescribe a new drug. Consultants rated independent sources of information more highly than non-independent sources. The most important factors reported to influence prescribing decisions about new drugs were drug characteristics, such as efficacy and safety, and evidence from scientific literature. Sixty-four respondents (70 per cent) saw drug company representatives up to once a week and 57 (62 per cent) had been involved in clinical trials of new drugs in the previous five years. Conclusion In general, the consultants reported that they used only a small number of new drugs. There is considerable pressure on hospital doctors to control prescribing and costs of new drugs through policies that require approval by the drug and therapeutics committee. Although contact with the pharmaceutical industry was high, consultants reported that independent sources of information were more important. Factors such as clinical trial evidence and improved drug characteristics were said to be the most influential in reaching decisions to prescribe new drugs.Keywords
This publication has 9 references indexed in Scilit:
- Reasons for not seeing drug representativesBMJ, 1999
- A review of methods of drug cost management in hospitalsJournal of Clinical Pharmacy & Therapeutics, 1998
- New active substances authorized in the United Kingdom between 1972 and 1994British Journal of Clinical Pharmacology, 1998
- Too soon to marketBMJ, 1997
- Buccaling under the pressure: influence of secondary care establishments on the prescribing of glyceryl trinitrate buccal tablets in primary careBMJ, 1996
- Clinical trials and clinical practiceThe Lancet, 1993
- Prescribing at the hospital-general practice interface. I: Hospital outpatient dispensing policies in England.BMJ, 1992
- How to pay for expensive drugs.BMJ, 1991
- Patterns of preference for information sources in the adoption of new drugs by specialistsSocial Science & Medicine, 1990